|
Zomedica Corp., a veterinary health company offering diagnostic and therapeutic solutions for equine and companion animals, announced a collaboration with Boehringer Ingelheim Animal Health Canada Inc., a leader in the animal health industry, to enhance the early detection, treatment, and monitoring of pituitary pars intermedia dysfunction (PPID) in horses across Canada.
Through this initiative, the TRUFORMA system will support Boehringer Ingelheim's PPID awareness and testing efforts in Canada beginning with this fall testing season, enabling veterinarians to perform rapid endocrine testing at the point of care using Zomedica's equine endogenous ACTH (eACTH) and equine insulin assays.
By bringing this testing directly into equine veterinary practices, the program will support prompt diagnosis and treatment. The use of Zomedica's TRUFORMA diagnostic platform within Boehringer Ingelheim's PPID awareness and testing efforts brings advantages for Canadian veterinarians and horse owners alike.
Under the agreement, Zomedica will support the placement of TRUFORMA analyzers in participating equine veterinary practices across Canada, while Boehringer Ingelheim will provide eligible customers with complimentary diagnostic testing performed using Zomedica's TRUFORMA platform.
Participation in the programme includes no-cost placement of TRUFORMA analyzers in participating equine veterinary practices, along with diagnostic cartridge kits provided at no cost to eligible Boehringer Ingelheim customers. This approach is expected to expand the installed base of Zomedica's platform in Canada and introduce participating veterinarians to additional equine assays available from Zomedica, including Cortisol and Progesterone.
PPID, previously known as equine Cushing's disease, is the most common endocrine disorder in aging horses, affecting approximately 20-25% of horses over the age of 15. This prevalence has been documented in multiple epidemiological studies, including research published in the Journal of Veterinary Internal Medicine, which reported that roughly one-fifth of horses over 15 years of age show evidence of PPID based on endocrine testing (McFarlane et al., Journal of Veterinary Internal Medicine, 2018).
The programme will utilize Zomedica's TRUFORMA equine endogenous ACTH (eACTH) assay, which recent comparative evaluation data has demonstrated to have the closest agreement to reference laboratory results when compared with other commercially available assays, supporting its reliability for diagnosing PPID and monitoring treatment response.
"Expanding our collaboration with Boehringer Ingelheim-one of the largest and most respected companies in global animal health-into Canada, represents another important milestone for Zomedica," said Kevin Klass, senior vice president, sales at Zomedica. "Their leadership in equine medicine, combined with our TRUFORMA diagnostic technology, creates a powerful synergy and marks another critical step in our strategy. Canada's vast geography and dispersed equine veterinary practices make access to specialized testing more challenging. Bringing this capability into the clinic will reduce the impact of distance and geographic isolation, facilitating timely testing."
"Veterinarians play a critical role in recognizing and managing PPID, and we've seen the meaningful difference that early diagnosis, treatment, and whole-horse management can make," commented Randy Trumpler, business unit director - Equine at Boehringer Ingelheim Animal Health Canada Inc. "By collaborating with Zomedica, we're expanding access to innovative diagnostic solutions for Canadian veterinarians and empowering them to make faster, more confident decisions-ultimately supporting better outcomes for the horses in their care and their owners."
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Its gold standard PulseVet shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics.
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need.
Boehringer Ingelheim?(Canada) provides innovation for preventing and treating diseases in animals. The company offers a wide range of vaccines, parasite-control products, and medicines for pets, horses, and livestock to veterinarians, animal owners, farmers, and governments. As a leader in animal health, Boehringer Ingelheim values that the health of humans and animals is deeply connected and strives to make a difference for people, animals and society.
|